RxDoctor Payments DataLook up a doctor →

Daniel Petrylak, MD

Medical Oncology · New Haven, CTNPI 1659387306

Payments from drug & device makers

$10,001,541in general payments, 2019–2025

Across 1,569 payments — averaging $6374.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.7M
  • Seagen Inc.$1.3M
  • Medivation LLC.$938K
  • Pfizer$824K
  • Astellas Pharma Global Development$765K
  • Gilead$698K
  • plus $3.8M from 50 others
$76,172in research payments, 2019–2025

Across 204 payments — averaging $373.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$56K
  • Pfizer$13K
  • F. Hoffmann-la Roche AG$4K
  • Eli Lilly$2K
  • Amgen$810
  • Seagen Inc.$65

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck106$1,698,531
Seagen Inc.216$1,300,944
Medivation LLC.64$937,924
Pfizer203$824,071
Astellas Pharma Global Development132$765,182
Gilead85$698,194
Amgen15$603,120
Pharmaand GmbH4$502,762
Genentech, Inc.145$479,301
AstraZeneca97$452,555
E.r. Squibb & Sons, L.L.C.20$305,904
Astrazeneca UK Limited13$270,644
Clovis Oncology, Inc.93$200,322
Novartis9$163,014
Exelixis Inc.50$161,499
F. Hoffmann-la Roche AG21$106,949
Bayer29$59,268
Daiichi Sankyo Inc.20$58,863
Eli Lilly17$48,730
Bioxcel Therapeutics, Inc.14$44,021
Mirati Therapeutics, Inc.10$42,406
Janssen Scientific Affairs, LLC22$23,100
Sanofi14$23,026
Astellas Pharma Europe Ltd24$21,885
Ferring International Pharmascience Center US5$20,610
Sanofi US Services Inc.2$19,640
Ipsen Biopharmaceuticals, Inc15$17,004
Progenics Pharmaceuticals, Inc.9$13,969
Janssen Global Services, LLC9$13,108
EMD Serono, Inc.22$12,950
Johnson & Johnson11$11,851
Astellas Pharma US Inc8$10,343
Immunomedics, Inc.3$9,323
Ferring Pharmaceuticals Inc.7$7,307
Advanced Accelerator Applications4$6,782
Theratechnologies Inc.5$6,335
Ferring Pharmaceuticals AS8$5,870
AVEO Pharmaceuticals, Inc.3$5,252
Myovant Sciences Inc.1$4,725
Merck Kgaa2$4,518
Ares Trading SA1$4,500
Lantheus Medical Imaging, Inc.5$4,370
Bristol Myers Squibb4$4,136
Regeneron1$3,930
Taiho Oncology, Inc.1$3,750
Astellas Pharma Inc1$3,720
Janssen Research & Development, LLC2$3,343
ADC Therapeutics America, Inc.3$3,000
Dendreon Pharmaceuticals LLC3$2,325
Boehringer Ingelheim International GmbH2$2,202
GSK1$1,600
Aadi Bioscience, Inc.1$1,500
Tolmar, Inc.1$790
Blue Earth Diagnostics4$435
Sumitomo Pharma America, Inc.1$84
Roche Products Limited1$53

How this compares

$10,001,541 in reported general payments places this provider in the 95th percentile of 79 medical oncology providers in Connecticut.

See all medical oncology providers in Connecticut →

Medicare billing

Part B allowed, 2024
$83,912
Medicare patients
265
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in New Haven

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →